Wall Street Zen Downgrades MiNK Therapeutics (NASDAQ:INKT) to Sell

by · The Cerbat Gem

MiNK Therapeutics (NASDAQ:INKT – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Other equities analysts have also recently issued research reports about the stock. Zacks Research upgraded shares of MiNK Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, October 20th. Weiss Ratings restated a “sell (d-)” rating on shares of MiNK Therapeutics in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $35.00.

Read Our Latest Research Report on INKT

MiNK Therapeutics Stock Up 0.5%

Shares of MiNK Therapeutics stock opened at $11.59 on Friday. The business has a 50 day moving average of $12.75 and a 200 day moving average of $13.63. MiNK Therapeutics has a 52 week low of $4.56 and a 52 week high of $76.00. The company has a market cap of $54.36 million, a PE ratio of -3.83 and a beta of 0.35.

MiNK Therapeutics (NASDAQ:INKT – Get Free Report) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.21. On average, research analysts anticipate that MiNK Therapeutics will post -2.75 earnings per share for the current year.

About MiNK Therapeutics

(Get Free Report)

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.

See Also